title: Synchronous well differentiated neuroendocrine tumour and gastrointestinal stromal tumour of the stomach: a case report.
abstract: BACKGROUND
  Well differentiated neuroendocrine tumours (carcinoids), arising from cells of the diffuse neuroendocrine system, represent the most commonly encountered gastric endocrine tumours. Gastrointestinal stromal tumours (GISTs), which stem from interstitial Cajal cells located within the wall of the gastrointestinal tract and have a characteristic immunoreactivity for CD117 (c-kit protein), account for the majority of gastrointestinal mesenchymal neoplasms. Simultaneous occurrence of a GIST with a well differentiated neuroendocrine tumour in the stomach is very rare.
  
  
  METHODS
  Clinical history, endoscopy and histopathological findings were utilized for our diagnostic considerations.
  
  
  RESULTS
  We report the coexistence of a high risk GIST with a well differentiated neuroendocrine tumour of benign clinical behavior, both located in the stomach, in a 62-year-old man previously operated for a gastric well differentiated neuroendocrine tumour with uncertain malignant behaviour.
  
  
  CONCLUSIONS
  Even single well differentiated, sporadic, NETs of small size may coexist with GISTs. An appropriate initial therapeutic approach combined with a scrupulous follow-up seems to play a significant role in terms of preventing a metastatic disease.
authors: 2ndDepartment of Pathology, University of Athens Medical School, Attikon University Hospital, Athens, Greece. vassilissamaras@yahoo.gr
authors: Vassilis D
authors: VD
authors: Samaras
authors: Periklis G
authors: PG
authors: Foukas
authors: Konstantinos
authors: K
authors: Triantafyllou
authors: Vassilia
authors: V
authors: Leontara
authors: Dimitrios
authors: D
authors: Tsapralis
authors: Eirini M
authors: EM
authors: Tsompanidi
authors: Anastasios
authors: A
authors: Machairas
authors: Ioannis G
authors: IG
authors: Panayiotides
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000378:metabolism; D003131:Combined Modality Therapy; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D005773:Gastroscopy; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit